The American Congress of Obstetricians and Gynecologists (ACOG) has updated its recommended therapy for pregnant women with an opioid-use disorder. The new guidance includes treatment options and screening recommendations pioneered by Craig Towers, MD, Professor of Obstetrics and Gynecology and a maternal-fetal medicine specialist.
On February 6, 2016, at the Society for Maternal-Fetal Medicine’s annual meeting in Atlanta, Dr. Towers unveiled important research findings on a study he lead, showing evidence that maternal opiate detoxification during pregnancy significantly improves pregnancy outcome, without putting the fetus at risk.
Additionally, Dr. Towers’s findings were published in some of the nation’s leading obstetrics and gynecology publications and his work at the University of Tennessee Graduate School of Medicine has been profiled by national media outlets including CNN and Modern Healthcare magazine.
“As opiate addiction increasingly creeps into the pregnant population, mothers expose their unborn babies to drugs that often cause Neonatal Abstinence Syndrome (NAS),” said Dr. Towers. “Identifying opiate addicted pregnant women, getting them into a program that can first medically withdraw them and then be supported by follow-ups to further aid a drug-free lifestyle is of paramount importance.”
According to ACOG, opioid agonist pharmacotherapy, also known as medication-assisted treatment (MAT), continues to be the recommended therapy for pregnant women with an opioid use disorder. However, this new guidance, spearheaded by Dr. Towers, also recognizes that medically supervised withdrawal can be considered under the care of a physician experienced in perinatal addiction treatment if a woman does not accept MAT.
“I am glad to hear ACOG is recognizing that medically supervised withdrawal under the care of an experienced physician can be offered to pregnant women with opioid use disorder as an additional option beyond MAT,” said Dr. Towers. “This approach is very successful when connected with behavioral health and results in babies born who do not suffer NAS.”
Posted July 27, 2017
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2019